EcoR1 Capital LLC 13D and 13G filings for Neoleukin Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 3:03 pm Sale | 2021-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | EcoR1 Capital LLC | 43,031 2.000% | -113,104 (-72.44%) | Filing |
| 2021-02-16 12:05 pm Sale | 2020-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | EcoR1 Capital LLC | 156,135 7.500% | -39,659 (-20.26%) | Filing |